جستجوی مقالات مرتبط با کلیدواژه « مایکوفنولات موفتیل » در نشریات گروه « پزشکی »

Mycophenolate mofetil as an immunosuppressive agent is widely administered in patients with kidney disorders and following organ transplantation. The amounts of xanthan gum and sorbitol, as two excipients of mycophenolate mofetil, are influential on the final quality and stability of the suspension. 

In this experimental study, we aim to optimize the levels of xanthan gum and sorbitol in the Mycophenolate mofetil powder. 
Methods A Central composite design was used to prepare the formulations. The amounts of xanthan gum and sorbitol were considered as independent variables while the sedimentation volume (F value) and concentration of active pharmaceutical ingredient (API) after preparation and after 3 months of storage at 45 ͦC were considered as dependent variables. The samples were prepared through wet granulation process. Chromatography analysis and determination of F value and API were then performed. 

Analysis of variance showed that the increase in the amounts of xanthan up to 75 mg provided higher F value and better protection of API after 3 months by 98%, while the increase of sorbitol from 10 to 25 g had no significant effect on these variables. Optimized sample composed of 16.69 g sorbitol and 68.81 mg xanthan gum. Predicted error was desirably less than 5%. 

The proposed formulation of mycophenolate mofetil powder for oral suspension with optimum amounts of xanthan gum and sorbitol has good stability. High level of xanthan gum and moderate level of sorbitol are recommended for preparing an optimal product.

Pemphigus is one of the most common types of autoimmune blistering disease that requires systemic immunosuppressive therapy. Immunosuppressive therapy has improved the disease outcome in recent decades، but long-term use of them has side effects. Recently، it has been tried to evaluate immunosuppressive drugs with less side effects. One of them is mycophenolate mofetil. The aim of this study was to evaluate of therapeutic efficacy of this drug in the patients with refractory pemphigus vulgaris.

Three hundred files of patients with pemphigus vulgaris were reviewed and among them 28 patients who had received mycophenolate mofetil due to resistance to treatment were entered to this study. The data were obtained from patients’ files and were analyzed using Kendall''s tau-c correlation، Mann-Whitney and ANOVA tests.

Male to female ratio was 1. 8:1 with an average age of 43. 3±13. 6 year. Twenty-eight cases of pemphigus vulgaris were treated receiving 2gr/day mycophenolate mofetil + 1mg/kg/day prednisolone. Remission occurred after 3 months. Seventeen patients (10 men and 7 women) had complete remission. There was no significant association between gender and treatment response (P=0. 58). There was no significant association between mean age of treated patients and untreated patients with treatment response (P=0. 77). Also، there was no significant association between severity of mucosal (P=0. 80) and severity of skin involvement with treatment response (P=0. 80). Ten patients who received mycophenolate mofetil more than 12 months had treatment response to mycophenolate mofetil and they did not have any relapse in the follow up period.

Mycophenolate mofetil is effective and safe as an adjuvant therapy in patients with pemphigus vulgaris especially in refractory pemphigus. Initiation of the therapeutic effect is slow.